Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...